Baxter news

As part of a company-wide restructuring, Baxter's directors approved a series of business plan changes that includes the investment of $2 billion into "high-growth health care" businesses over the next three years.

The company said its renal, biotechnology, cardiovascular and international hospital products businesses will receive increased investments. Baxter's biotechnology interests include gene therapy, immunotherapy, blood substitutes and a hylan division. ...